Brian Goff - 08 Aug 2022 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: AGIO
Reported as of: 08 Aug 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Aug 2022, 16:50:33 UTC
Prior SEC filing: 23 Jul 2021
Next SEC filing: 03 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ William Cook, as Attorney in Fact for Brian Goff

Key filing fact

Brian Goff filed Form 4 for AGIOS PHARMACEUTICALS, INC. (AGIO) on 09 Aug 2022.

Key facts

This page summarizes Brian Goff's Form 4 filing for AGIOS PHARMACEUTICALS, INC. (AGIO).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 09 Aug 2022, 16:50.

Change

Previous filing in this sequence was filed on 23 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGIO transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +561,083
Change %
Price: $0.000000
Shares after: 561,083
Date: 08 Aug 2022
Ownership: Direct
Underlying class: Common stock
Underlying amount: 561,083
Exercise price: $29.38
Footnotes: F1

AGIO transaction Derivative

Restricted stock units

Award

Transaction value: $0
Shares: +68,073
Change %
Price: $0.000000
Shares after: 68,073
Date: 08 Aug 2022
Ownership: Direct
Underlying class: Common stock
Underlying amount: 68,073
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This option was granted on August 8, 2022. The shares underlying this option vest as to 25% of the underlying shares on August 8, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Footnote F3

The restricted stock units were granted on August 8, 2022. Beginning on August 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.